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Abstract
Background: Molecular oncology testing (MOT) to detect genomic alterations underlying cancer holds
promise for improved cancer care. Yet knowledge limitations regarding the delivery of testing services may
constrain the translation of scientific advancements into effective health care.
Methods: We conducted a cross-sectional, self-administered, postal survey of active cancer physicians in
Ontario, Canada (N = 611) likely to order MOT, and cancer laboratories (N = 99) likely to refer (i.e.,
referring laboratories) or conduct (i.e., testing laboratories) MOT in 2006, to assess respondents'
perceptions of the importance and accessibility of MOT and their preparedness to provide it.
Results: 54% of physicians, 63% of testing laboratories and 60% of referring laboratories responded. Most
perceived MOT to be important for treatment, diagnosis or prognosis now, and in 5 years (61% – 100%).
Yet only 45% of physicians, 59% of testing labs and 53% of referring labs agreed that patients in their region
were receiving MOT that is indicated as a standard of care. Physicians and laboratories perceived various
barriers to providing MOT, including, among 70% of physicians, a lack of clear guidelines regarding clinical
indications, and among laboratories, a lack of funding (73% – 100%). Testing laboratories were confident
of their ability to determine whether and which MOT was indicated (77% and 82% respectively), and
perceived that key elements of formal and continuing education were helpful (75% – 100%). By contrast,
minorities of physicians were confident of their ability to assess whether and which MOT was indicated
(46% and 34% respectively), and while majorities considered various continuing educational resources
helpful (68% – 75%), only minorities considered key elements of formal education helpful in preparing for
MOT (17% – 43%).
Conclusion: Physicians and laboratory professionals were enthusiastic about the value of MOT for cancer
care but most did not believe patients were gaining adequate access to clinically necessary testing. Further,
our results suggest that many were ill equipped as individual stakeholders, or as a coordinated system of
referral and interpretation, to provide MOT. These challenges should inspire educational, training and
other interventions to ensure that developments in molecular oncology can result in optimal cancer care.
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Background
Personalized or 'targeted' oncology is made possible by
scientific developments identifying the genetic and
genomic alterations underlying cancer. Some of these
alterations are hereditary in nature and have particular rel-
evance for individuals with high-risk family histories, but
most are acquired genomic alterations with relevance to all
forms of malignancy. Increased understanding of the sig-
nificance of acquired genomic alterations in malignancy
holds considerable promise for improved cancer care but
knowledge about the delivery of associated laboratory
services is limited, constraining the ability to translate sci-
entific advancements into improvements in cancer care
[1-6].
Molecular oncology testing for acquired genomic altera-
tions in cancer (MOT) can provide more refined diag-
noses and more accurate prognoses, contributing to the
molecular classification of malignancies. Indeed, some
sporadic cancers are already defined and named according
to their genetic characteristics (e.g., for acute myeloid
leukemia, (AML) M3 with t(15;17), AML with t(8;21), or
AML with inv16); a trend that is expected to increase[7,8].
However, molecular oncology testing is important for
more than disease classification. Decisions about therapy
are also informed by such testing, with sub-types and
prognostic markers sometimes used to guide more aggres-
sive approaches to treatment[9,10]. Further, molecular
oncology testing has special relevance where specific
biomarkers can guide targeted therapy. For example, clin-
ical guidelines recommend treatment with Trastuzumab
in patients with early stage breast cancer in which the
human epidermal growth factor-like receptor No 2 (HER-
2) is overexpressed[11]. Thus, laboratory testing, includ-
ing MOT, is necessary to assess the status of the HER2
oncogene in most breast cancer patients, to guide the
appropriate use of this expensive therapeutic [12-15].
More recently, the use of biological therapeutics such as
Panitumumab for metastatic colorectal carcinoma require
MOT for detection of mutations in the KRAS gene before
patients are eligible for treatment with this antibody[16].
To date, research on the delivery of genetic testing services
has focused on testing for germline changes associated
with hereditary disease [17-19], or molecular genetic test-
ing more generally [20-22]. Much research has been moti-
vated by policy interest in genetic testing, where such
testing is defined broadly to include heritable or acquired
genetic changes[23]. For example, a recent "horizon scan"
review by the US Agency for Healthcare Research and
Quality (AHRQ) adopts such a definition in identifying
the genetic tests relevant to cancer care that are both clin-
ically available and under development http://
www.ahrq.gov/clinic/ta/gentests/gentests.pdf. Yet while
attention to the effective provision of health services for
hereditary disease is needed, and will increase as germline
genetic testing expands with the development of high
throughput technologies, the scope and significance of
molecular oncology testing for sporadic disease still war-
rants focused attention. Indeed, unlike the relatively small
proportion of cancers that are hereditary and for which
germline genetic testing is relevant, molecular oncology
testing for the acquired genomic changes underlying spo-
radic cancer is potentially relevant to all forms of malig-
nancy. Further, the delivery of these services is unlikely to
require a genetic modality of care, where testing is offered
alongside genetic counselling and within specialized
genetic clinics[24].
The effective and appropriate delivery of molecular oncol-
ogy testing for sporadic cancer relies on a coordinated sys-
tem of referral and interpretation involving both
physicians and laboratory professionals. In Ontario, Can-
ada, appropriate referral is a responsibility of physicians
who request laboratory analysis, and those cancer labora-
tories that receive patient samples for testing but lack the
capacity to conduct MOT. Such "referral laboratories"
must submit relevant samples to the smaller number of
"testing laboratories" in the province with the profes-
sional and technological credentials to conduct MOT.
These testing laboratories must then conduct and report
on relevant molecular oncology analyses, providing a
report to the referring physician that can inform clinical
decision-making.
Access to most laboratory cancer services is free to resi-
dents of Ontario at the point of care, as part of the pub-
licly-funded Medicare system. While this minimizes the
significance of financial constraints for the patient, finan-
cial constraints are not irrelevant to involved health pro-
fessionals. Little of the provincial funding for complex test
technologies is allotted per test, or for a volume of testing.
Instead, hospital-based laboratories incorporate the costs
of much of the relevant testing within capped global
budgets. Decisions about which tests to provide or adopt
are therefore constrained, potentially leading to delays in
the uptake of relevant tests. Further, physicians may be
aware of tests that they deem clinically useful that are not
provided through provincially funded labs. While the
province has a pre-approval system for the public cover-
age of testing conducted out-of-province, it can be cum-
bersome and time consuming; further, physicians seeking
more rapid access to relevant tests would pass on any asso-
ciated costs to patients. Meanwhile, some physicians
might be uncertain about the extent to which relevant
tests would be made available to patients free at the point
of care.
Discovery research on genomic technologies with applica-
tion to cancer care is developing at a rapid pace. Yet trans-BMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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lational research to move validated discoveries into health
care practice, through research on the delivery, dissemina-
tion and diffusion of innovations – dubbed "T3" by
Khoury and colleagues – has fallen behind[25]. A recent
publication by Wideroff and colleagues reports the delib-
erations of a US National Cancer Institute workshop that
examined the state of health services research on these
and related technologies, and called for a comprehensive
health services research agenda to address existing defi-
ciencies, including research on utilization, access and pro-
vider preferences[1]. In the absence of a body of health
services research on MOT, we conducted a postal survey
examining the attitudes and practices of laboratories that
perform MOT (i.e., testing laboratories), laboratories that
refer samples for MOT (i.e., referring laboratories), and
physicians who order or utilize MOT results in Ontario.
The study was designed to be exploratory and descriptive
– to identify the attitudes and reported practices of key
stakeholder groups, provide a baseline data set, and sug-
gest areas of concern for future hypothesis-driven
research. Because of the importance of coordinated
approaches to referral and testing for the appropriate and
effective delivery of these laboratory services, we were
especially interested to identify differences in attitudes
between physicians, referring laboratories and testing lab-
oratories. In addition, because we expected that physi-
cians might vary considerably in their ability to make
effective use of MOT services, we were interested to
explore whether certain physician characteristics (e.g.,
being a specialist provider, or provider of care for the
hematological malignancies, etc.) were consistently asso-
ciated with reported attitudes, and with the anticipated
valence.
Methods
With ethics approval from McMaster University's Research
Ethics Board, we conducted a cross-sectional, self-admin-
istered postal survey of physicians and laboratories in
Ontario, Canada in 2006. Questionnaires were sent to
611 cancer physicians in Ontario who were likely to order
or use MOT. This included physicians identified as oncol-
ogists, and other physicians with a medical specialty or
interest in oncology as defined by MDSelect, the Cana-
dian Medical Directory, made available for purchase by
the Canadian Medical Association (e.g., hematologists or
gynecologists with a sub-specialty in oncology, family
physicians with a medical interest in oncology, etc.).
In addition, we sent questionnaires to 99 hospital-based,
public laboratories in Ontario that were likely to (1) con-
duct MOT, hereinafter testing laboratories; or (2) receive
cancer samples where MOT testing might be indicated
and, in the absence of on-site capacity, refer these samples
to testing laboratories for relevant analyses, hereinafter
referring laboratories. Relevant sites included genetics,
hematology and pathology laboratories involved in
assessing cancer samples. We identified potential labora-
tories through publicly available lists of Ontario hospi-
tals, supplemented by telephone contact to clarify
whether MOT was referred out or conducted on-site, and
to identify one person (laboratory director, medical direc-
tor, technical director, site supervisor or senior patholo-
gist/hematologist) to whom a questionnaire regarding the
laboratory should be directed.
Up to five contacts were made with potential physician or
laboratory professional respondents over a 7 week period,
following a modified version of the Dillman Tailored
Design method[26]. The first mailing was a notice letter to
apprise potential respondents of the study. The second
mailing included a study package (cover letter, numbered
questionnaire, postage paid return envelope) and finan-
cial incentive ($5 gift certificate at a popular coffee shop).
The third mailing to everyone was a thank you/reminder
letter. The fourth mailing of a study package was sent to
non-respondents. For remaining non-respondents, a fifth
and final study package was sent by courier.
The questionnaire asked respondents about their involve-
ment with and attitudes toward molecular oncology test-
ing, which we explicitly and repeatedly defined as testing
for acquired genetic changes in solid tumours and hemato-
logical malignancies (e.g. c-kit, 1p19q, t(9;22), HER-2/
neu) involving cytogenetic and molecular genetic technol-
ogies (e.g., karyotyping, FISH, PCR, etc.). A multidiscipli-
nary team developed 3 versions of a purpose-designed
questionnaire for the 3 respondent groups (physicians,
testing laboratories, referring laboratories), after finding
no appropriate instrument in the literature. The question-
naire did not include validated items, though it was
informed by questions asked of respondents in other rel-
evant laboratory surveys[17,20-22]. It was pre-tested by
the study team and 2–4 potential respondents per version
using an iterative process to ensure face validity. The ques-
tionnaire was organized into 5 sections, 3 of which were
similar across the 3 respondent groups: (i) the importance
of MOT; (ii) training and continuing education for MOT;
and (iii) demographic information. The other two sec-
tions addressed issues of specific concern to each respond-
ent group, including questions (i) about the laboratory,
and (ii) service provision, for laboratories, and (i) role in
provision of MOT, and (ii) availability of MOT, for physi-
cians. Correspondingly, the length of the questionnaire
varied for each respondent group, with 150 items for phy-
sicians, 162 for referring laboratories and 195 items for
testing laboratories.
We report data on the characteristics of physicians and
laboratories and their reported involvement in MOT,
together with responses in 6 key attitude domains: (i)BMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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importance: the perceived importance of MOT relative to
other pathology or hematology testing for the diagnosis,
prognosis or treatment of cancer, now and in 5 years; (ii)
adequacy of access: perceptions regarding the adequacy
of access by cancer patients to MOT within the respond-
ent's region and Ontario, and in comparison to other
jurisdictions in Canada or the US; (iii) barriers to provid-
ing: the perceived barriers to providing MOT, differenti-
ated into those barriers seen to impede ordering MOT for
physicians, and those barriers perceived to impede con-
ducting MOT on-site, both for testing laboratories and
any referring laboratories wishing to do so; (iv) confi-
dence in assessing indications: reported confidence in
assessing whether MOT was clinically indicated, and if so,
which molecular oncology tests were indicated; in addi-
tion, because testing labs are expert providers of MOT and
well-positioned to assess the relevance of such testing for
particular types of cancers, we also asked testing laborato-
ries to indicate their confidence in the ability of physicians
and referring labs to make these determinations; (v)
responsibility of providers: attitudes regarding which
providers (physicians, referring laboratories, testing labo-
ratory physician or institution as a whole) were perceived
to appropriately determine which molecular oncology
tests were suitable for individual patients, and for integrat-
ing the results of MO testing with other laboratory results;
and (vi) educational preparedness: perceptions of how
helpful various elements of formal or continuing educa-
tion had been in preparing respondents to provide MOT
on the one hand, and to maintain knowledge of MOT on
the other. Additional items in the questionnaire addressed
more detailed aspects of physician and laboratory practice
in relation to MOT; a report of findings from these addi-
tional items is available, upon request, from the principal
author.
Data from completed questionnaires were entered using
the Snap Survey data entry tool (Version 8, Snap Surveys
Ltd). As an exploratory study, our analysis measured only
univariate associations. In the absence of clear prior
hypotheses, we did not make any distributional assump-
tions, nor pursue multivariate modeling. Descriptive sta-
tistics were computed for all variables measured,
including frequency counts and percentages. We used the
chi-square test or, when appropriate, Fisher exact test to
determine differences in categorical variables. Unadjusted
odds ratios (ORs), 95% confidence intervals (CIs) and p-
values are reported as appropriate. A probability level of <
0.05 was used to determine statistical significance. Physi-
cian data were analyzed using SPSS (Version 16). Labora-
tory data, and comparisons between laboratory and
physician data, were analyzed using WinPepi COMPARE2
v1.78.
Results
Response rate
317 completed questionnaires were received from a total
of 611 physicians contacted. During the course of the
study, we identified 21 of the 611 physicians as ineligible
and excluded them from the analysis giving us a corrected
response rate of 53.73%. Reasons for exclusion included
inability to locate physicians despite repeated efforts and
respondents reporting themselves as ineligible. 57 com-
pleted laboratory questionnaires were received from the
99 laboratories contacted (17 of 30 testing labs, 40 of 69
referring labs). During the course of the survey, we identi-
fied 5 labs as ineligible as they did not assess cancer sam-
ples or conduct relevant testing, resulting in a corrected
response rate of 60.64% (Table 1)
Characteristics and practices of respondents
Of the 317 completed physician questionnaires, 28 were
excluded for poor quality or because physicians ordered
no laboratory testing for cancer, leaving a total of 289
questionnaires for analysis (Table 2). The majority of
these respondents were male (68.2%), worked in aca-
demic teaching unit settings (58.7%), in metropolitan/
central city locations (59.1%), were medical specialists
Table 1: Response rates
Sample Original No. Completed surveys No. Response rate
(%)
Ineligible respondents No. Adjusted response rate (%)
Physicians 611 317 51.88 21* 53.73
Labs 99 57 57.58 5** 60.64
(Testing labs) (30) (17) (56.67) (3**) (62.96)
(Referring labs) (69) (40) (57.97) (2**) (59.70)
* Not in practice or could not be located despite repeated efforts.
** Lab did not assess cancer samples or conduct relevant testing.BMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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Table 2: Characteristics of physician respondents
Characteristic Respondents
No. (%)
Practice setting
Academic teaching unit 162/276 (58.7)
Not-academic teaching unit 114/276 (41.3)
Method of reimbursement
Fee for service 97/263 (36.9)
Not-fee for service 166/263 (63.1)
Geographic location
Metropolitan/central city 165/279 (59.1)
Metropolitan/suburban 58/279 (20.8)
Small city or town 44/279 (15.8)
Rural 12/279 (4.3)
Gender
Female 88/277 (31.8)
Male 189/277 (68.2)
Primary area of practice or expertise
Specialty 219/268 (81.7)
Medical oncology (81/268)
Radiation oncology (77/268)
Surgical oncology (24/268)
Hematology/Hematological oncology (20/268)
Gynecological oncology (9/268)
Medical and hematological oncology (3/268)
Non-oncologic specialists (general internal medicine, gastroenterology) (5/268)
Family medicine 49/268 (18.3)
Type of oncology practice
Solid tumours only 212/280 (75.7)
Hematological malignancies only 12/280 (4.3)BMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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(81.7%), provided care only for patients with solid
tumours (75.7%), and reported ordering any MOT
(67.2%) (defined as rarely, sometimes, usually or always).
Laboratories that performed MOT were more frequently
located in central cities than referring labs (64.7% and
32.5% respectively); they more frequently served catch-
ment areas with greater than 2,000,000 people (37.5%
and 8.1% respectively), and were more frequently housed
within academic health science centres (68.8% and 31.6%
respectively) rather than community hospitals. In addi-
tion, more testing than referring laboratories defined
themselves as molecular genetics (25.0% and 0% respec-
tively) or cytogenetics (31.3% and 0% respectively) labs.
These, and related, differences are statistically significant
(Table 3).
Attitudes toward the importance of MOT
We asked respondents to indicate the importance of MOT
relative to other pathology/hematology testing for the
diagnosis, prognosis or treatment of cancer now, and in
five years (using five-point Likert scales from not at all
important to very important) (Table 4). Respondents
shared a broadly positive opinion of the importance of
MOT. Majorities of physicians, referring laboratories and
testing laboratories considered MOT to be fairly or very
important for treatment, diagnosis or prognosis now, and
even larger majorities expressed these views for the impor-
tance of MOT in 5 years. Respondents differed, however,
in the extent to which they deemed MOT to be very impor-
tant. While the majority of testing labs judged MOT very
important for treatment, prognosis and diagnosis now
(70.6%, 64.7%, 76.5% respectively) and in 5 years
(93.8%, 93.8%, 87.5% respectively), only a quarter to a
half of physicians (24.6% through 52.2%) and referring
labs (30.8% through 46.2%) had the same degree of
enthusiasm; these differences are statistically significant.
Attitudes regarding access to MOT
We asked respondents to assess the adequacy of access by
cancer patients to MOT within their region and in
Ontario, and to compare access in Ontario to other
regions in Canada and the US (using five-point Likert
scales from strongly disagree to strongly agree) (Table 5).
Responses did not differ significantly between groups.
Attitudes were most positive regarding access in the
respondent's own region, though only 45.3% of physi-
cians, 58.8% of testing labs and 52.8% of referring labs
mildly or strongly agreed that patients in their region were
receiving MOT that is indicated as a standard of care. Even
fewer respondents (31.2% to 41.2%) mildly or strongly
agreed that cancer patients were receiving the standard of
care for MOT in the province of Ontario as a whole; fur-
ther, only 30.3% to 50% of respondents mildly or
strongly agreed that Ontario compared favourably to
other jurisdictions in Canada in ensuring clinically indi-
cated MOT, while fewer still (6.7% to 14.2%) agreed that
Ontario compared favourably with jurisdictions in the US
in ensuring access to the standard of care in MOT.
Perceived barriers to MOT
To explore perceived barriers in the provision of MOT
services, we identified a set of potentially relevant infor-
mational and material barriers and asked respondents to
rate their impact (using five-point Likert scales from no
impact to high impact) on their practice. Physicians were
asked about barriers that might impede their ability or
willingness to order MOT (Table 6). Laboratories, includ-
ing both testing laboratories that already conducted MOT,
and any referring laboratories that would like to provide
MOT on-site, were asked about any barriers that might
restrict their ability to provide MO testing (Table 7).
Among physicians, a lack of clear guidelines regarding
clinical indications for MOT was perceived to be the most
important barrier to ordering MOT (69.7% identified this
as having some or high impact). Other barriers perceived
to have some or high impact by a majority of physicians
included a lack of coverage by the provincial health insur-
ance plan (Ontario Health Insurance Plan, OHIP)
(53.7%), and a lack of knowledge about how to order
MOT (52.3%). Notably, only a quarter of physicians per-
ceived a lack of patient demand, or a lack of time or per-
sonnel to order or review MOT, as barriers that posed
some or a high impact (27.3% and 23.3% respectively).
Laboratory respondents perceived that most of the sug-
gested resource barriers had some or a high impact on
their practice, with the largest majorities perceiving the
several items that identified potential funding barriers
(e.g., lack of funding for technical staff, development of
new tests, or ongoing provision of tests, etc.) as having
Hematological malignancies and solid tumours 56/280 (20.0)
Ordering Behaviour
Order any MOT 193/287 (67.2)
Order no MOT 94/287 (32.8)
Table 2: Characteristics of physician respondents (Continued)BMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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Table 3: Characteristics of respondent laboratories
Testing Labs No. (%) Referring Labs No. (%) p-value
Geographic location
Metropolitan/central city 11/17 (64.7) 13/40 (32.5) 0.024
Metropolitan/suburban 4/17 (23.5) 9/40 (22.5) 1.000*
Small city/town 2/17 (11.8) 16/40 (40.0) 0.036
Rural 0/17 (0) 2/40 (5.0) 1.000*
Size of catchment area
0 – 500,000 2/16 (12.5) 21/37 (56.8) 0.003
500,000 – 2,000,000 8/16 (50.0) 13/37 (35.1) 0.310
Greater than 2,000,000 6/16 (37.5) 3/37 (8.1) 0.016*
Type of setting
Community hospital 3/16 (18.8) 26/38 (68.4) 0.001
Academic Health Science Centre 11/16 (68.8) 12/38 (31.6) 0.012
Research laboratory 2/16 (12.5) 0/38 (0) 0.084*
Type of laboratory
General pathology 1/16 (6.3) 22/38 (57.9) < 0.001
Anatomical pathology 1/16 (6.3) 9/38 (23.7) 0.249*
Hematopathology 2/16 (12.5) 0/38 (0) 0.084*
Hematology 1/16 (6.3) 3/38 (7.9) 1.000*
Cancer cytogenetics 1/16 (6.3) 0/38 (0) 1.000*
Cytology 0/16 (0) 2/38 (5.3) 1.000*
Flow cytometry 0/16 (0) 2/38 (5.3) 1.000*
Cytogenetics 5/16 (31.3) 0/38 (0) 0.001*
Molecular cancer genetics 1/16 (6.3) 0/38 (0) 0.296*
Molecular genetics 4/16 (25.0) 0/38 (0) 0.006*
* Fisher exact testBMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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some or high impact. Testing labs and those referring labs
that did wish to provide MOT on-site were also similar in
their perception of the two legal/regulatory barriers iden-
tified; only minorities of respondents perceived a lack of
appropriate test regulation and oversight, or the existence
of restrictive patents or licenses, as having some or high
impact. However, testing and referring laboratories dif-
fered regarding some other potential barriers, with differ-
ences regarding which barriers had a high impact reaching
statistical significance. For referring labs, the barrier of
greatest concern was a perceived lack of funding for capi-
tal equipment: 82.4% of referring labs perceived this as a
high impact barrier while only 40% of testing labs consid-
ered this a high impact barrier. Finally, the non-financial
factor that attracted the most concern among testing labs
was a perceived lack of clinical demand; significantly
more testing labs than referring labs considered this a high
impact barrier (40% and 5.9% respectively).
Confidence in assessing indications for MOT
We asked respondents to specify their confidence in their
ability to assess whether MO testing was clinically indi-
cated or which MO tests were clinically indicated (using
five-point Likert scales from not at all confident to very
confident). Because testing labs occupy the end of the
referral chain, we also asked testing labs to indicate their
confidence in the ability of physicians and referring labs
to make these determinations (Table 8).
A large majority of testing labs was fairly or very confident
of their ability to decide whether MOT was indicated
(76.5%). By comparison, referring labs and physicians
Table 4: Perceived importance of MOT for diagnosis, prognosis, treatment now and in 5 years
Physicians No. (%) Testing labs No. (%) Referring labs No. (%) p-value
Fairly important Very important Fairly important Very Important Fairly important Very important Very important
Treatment now 92/271 (33.9) 85/271 (31.4) 4/17 (23.5) 12/17 (70.6) 14/39 (35.9) 15/39 (38.5) 0.004
Prognosis now 127/273 (46.5) 78/273 (28.6) 5/17 (29.4) 11/17 (64.7) 13/39 (33.3) 16/39 (41.0) 0.004
Diagnosis now 98/272 (36.0) 67/272 (24.6) 3/17 (17.6) 13/17 (76.5) 13/39 (33.3) 12/39 (30.8) < 0.001
Treatment in 5 yrs 79/270 (29.3) 141/270 (52.2) 1/16 (6.2) 15/16 (93.8) 14/39 (35.9) 18/39 (46.2) 0.003
Prognosis in 5 yrs 95/274 (34.7) 140/274 (51.1) 1/16 (6.2) 15/16 (93.8) 16/39 (41.0) 18/39 (46.2) 0.003
Diagnosis in 5 yrs 97/272 (35.7) 109/272 (40.1) 2/16 (12.5) 14/16 (87.5) 16/39 (41.0) 15/39 (38.5) 0.001
Table 5: Perceived adequacy of access to MOT by cancer patients
Physicians No. (%) Testing labs No. (%) Referring labs No. (%) p-value
Mildly agree Strongly agree Mildly agree Strongly agree Mildly agree Strongly agree Mildly or strongly agree
Cancer patients are receiving the MOT that is indicated as a standard of care ...
...in my region 76/258 (29.5) 41/258 (15.9) 6/17 (35.3) 4/17 (23.5) 10/36 (27.8) 9/36 (25.0) 0.423
...in Ontario 58/253 (22.9) 21/253 (8.3) 3/17 (17.6) 4/17 (23.5) 10/37 (27.0) 4/37 (10.8) 0.535
Ontario compares favorably in ensuring access to MOT that is indicated as a standard of care with...
... other jurisdictions in 
Canada
49/254 (19.3) 28/254 (11.0) 5/14 (35.7) 2/14 (24.3) 8/36 (22.2) 4/36 (11.1) 0.296
... other jurisdictions in 
the US
25/253 (9.9) 11/253 (4.3) 0/15 (0) 1/15 (6.7) 2/34 (5.9) 2/34 (5.9) 0.878*
*Fisher exact testBMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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had less confidence in themselves in this domain (61.5%
and 46% respectively were fairly or very confident). A
majority of testing labs was also fairly or very confident of
their ability to decide which MOT was required (82.4%);
again, referring labs and physicians had less confidence
regarding their own abilities (59% and 34.4% respectively
were fairly or very confident). A majority of testing labs
was fairly or very confident (70.6%) in the ability of phy-
sicians to determine whether MOT was required; but only
a minority (5.9%) was fairly or very confident in referring
labs to make this determination. Testing labs had less con-
fidence in physicians to decide which MOT was indicated
(47.1% were fairly or very confident) and no confidence
(0% were fairly or very confident) in referring labs to
make this determination.
Preferred roles of clinicians and laboratories in managing 
MOT
The coordination of MO laboratory services involves the
referring physician, the referring laboratory and two ele-
ments of the testing laboratory: the laboratory physician
(i.e., hematologist/pathologist), and the laboratory as a
reporting institution (i.e., not necessarily a physician reg-
istered to practice medicine in Ontario). To understand
Table 6: Physician perception of barriers to ordering MOT
Some impact No. (%) High impact No. (%)
Lack of clear guidelines re. indications for MOT 82/261 (31.4) 100/261 (38.3)
Lack of Ontario Health Insurance Plan (OHIP) coverage 64/257 (24.9) 74/257 (28.8)
Lack of knowledge about how to order MOT 75/258 (29.1) 60/258 (23.3)
Lack of accessible lab services 77/257 (30.0) 49/257 (19.1)
Lack of knowledge about how to interpret MOT results 68/260 (26.2) 53/260 (20.4)
Lack of patient demand/interest 48/257 (18.7) 22/257 (8.6)
Lack of time or personnel to order or review MOT 43/258 (16.7) 17/258 (6.6)
Table 7: Laboratory perception of barriers to providing MOT (for testing labs and referring labs that wished to conduct MOT on-site)
Testing labs No. (%) Referring labs@ No. (%) p-value
Some impact High impact Some impact High impact High impact
Lack of funding for capital equipment 5/15 (33.3) 6/15 (40.0) 2/17 (11.8) 14/17 (82.4) 0.014
Lack of funding for technical staff 5/16 (31.2) 11/16 (68.8) 3/17 (17.6) 13/17 (76.5) 0.708*
Lack of funding for development of new tests (test work up) 6/16 (37.5) 10/16 (62.5) 4/17 (23.5) 12/17 (70.6) 0.622
Lack of funding for ongoing provision of tests 8/16 (50.0) 8/16 (50.0) 3/17 (17.6) 12/17 (70.6) 0.226
Lack of qualified technical staff 6/16 (37.5) 4/16 (25.0) 2/17 (11.8) 9/17 (56.3) 0.101
Lack of MDs and/or PhDs with appropriate expertise 6/16 (37.5) 3/16 (18.8) 3/17 (17.6) 6/17 (37.5) 0.438*
Lack of clinical demand 1/15 (6.7) 6/15 (40.0) 3/17 (17.6) 1/17 (5.9) 0.033*
Lack of appropriate test regulation and oversight 3/15 (20.0) 2/15 (13.3) 1/17 (5.9) 0/17 (0) 0.212*
Existence of restrictive patents or licenses 2/16 (12.5) 3/16 (18.8) 1/17 (5.9) 1/17 (5.9) 0.335*
@Referring labs were told to skip the question if they did not want to provide MOT on-site
*Fisher exact testBMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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how respondents believed responsibilities should be
shared among these stakeholders, we asked which parties
should play a determining role in choosing the appropriate
MOT and in integrating MOT results with other results to
inform clinical practice (Table 9).
In considering who should choose  appropriate MOT,
respondent groups did not differ significantly regarding
the role of the referring laboratory or laboratory physi-
cian; few physicians, testing labs or referring labs indi-
cated that the referring laboratory should play a
determining role (8.5%, 6.3%, 15.2% respectively), while
approximately one-third suggested that the laboratory
physician should play a determining role (37.1%, 37.5%,
40.5% respectively). However, respondents did differ sig-
nificantly regarding the relative roles of referring clini-
cians and testing laboratories. Physicians preferred that
referring clinicians play a determining role (73%) and
only 5.8% of physicians suggested this role for the testing
laboratory. By contrast, 50% of testing labs preferred that
testing labs play a determining role, while only 31.3%
suggested that referring clinicians should have a determin-
ing role. Referring labs took an intermediate stance;
55.3% preferred that the referring clinician play a deter-
mining role and only 27.3% suggested that the testing lab
Table 8: Stated confidence in assessing indications for MOT
Physicians about 
selves No. (%)
Referring labs about 
selves No. (%)
Testing labs about 
testing labs No. (%)
Testing labs about 
physicians No. (%)
Testing labs about 
referring labs No. (%)
Fairly Very Fairly Very Fairly Very Fairly Very Fairly Very
Whether 
MOT is 
indicated
102/276 
(37.0)
25/276 
(9.1)
21/39 
(53.8)
3/39 (7.7) 8/17 (47.1) 5/17 (29.4) 11/17 
(64.7)
1/17 (5.9) 1/17 (5.9) 0/17 (0)
Which 
MO tests 
are 
indicated
75/276 
(27.2)
20/276 
(7.2)
19/39 
(48.7)
4/39 (10.3) 9/17 (52.9) 5/17 (29.4) 7/17 (41.2) 1/17 (5.9) 0/17 (0) 0/17 (0)
Table 9: Attitudes regarding who should play a determining role in MOT services
Physicians No. (%)^ Testing labs No. (%)^ Referring labs No (%)^ p-value
Choose appropriate MOT
Referring clinician 195/269 (73.0) 5/16 (31.3) 21/38 (55.3) 0.001*
Laboratory pathologist/hematologist 99/268 (37.1) 6/16 (37.5) 15/37 (40.5) 0.942
Referring laboratory 22/260 (8.5) 1/16 (6.3) 5/33 (15.2) 0.363*
Reporting laboratory 15/258 (5.8) 8/16 (50.0) 9/33 (27.3) < 0.001*
Integrate MOT results
Referring clinician 217/268 (81.3) 9/16 (56.3) 31/38 (81.6) 0.055
Laboratory pathologist/hematologist 81/265 (30.6) 11/17 (64.7) 17/37 (45.9) 0.004
Referring laboratory 22/251 (8.8) 0/16 (0) 7/33 (21.2) 0.043*
Reporting laboratory 15/252 (6.0) 4/16 (25.0) 7/34 (20.6) 0.001*
^Respondents could select more than one agent as having the 'determining role'; columns do not add to 100%
*Fisher exact testBMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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should play a determining role in choosing appropriate
MOT.
Attitudes regarding who should determine laboratory
result integration showed a similar pattern. Majorities of
respondent groups (56.3% of testing labs, 81.3% of phy-
sicians, 81.6% of referring labs) suggested that the refer-
ring clinicians should play a determining role. Yet 64.7%
of testing laboratories preferred that laboratory physicians
play a determining role – an option supported by only a
minority of physicians (30.6%) and referring labs
(45.9%). And while approximately one quarter of testing
and referring laboratories (25%, 20.6% respectively) sug-
gested that the testing lab should have a determining role,
only 6% of physicians agreed.
Reported educational preparedness for MOT
We asked respondents how helpful formal or continuing
education had been in preparing them for, or allowing
them to maintain their knowledge of, MOT (using five-
point Likert scales from not at all helpful to very helpful)
(Table 10). On balance, testing and referring laboratories
reported being fairly well equipped by formal and contin-
uing education to prepare for and maintain their knowl-
edge of MOT, though respondents from testing and
referring laboratories differed in terms of which formal
educational resources had supported them. Respondents
from testing laboratories relied on PhD training and post-
PhD clinical training to equip them, and majorities
reported these as fairly or helpful resources. Respondents
from referring labs relied more heavily on undergraduate
and post-graduate medical education, and most of these
found such resources fairly or very helpful. Respondents
from both testing and referring laboratories shared posi-
tive views regarding the helpfulness of most continuing
educational resources, with majorities perceiving most
identified resources as fairly or very helpful in maintain-
ing knowledge of MOT.
By contrast, physicians were significantly less well served
by their formal education; only 16.6% reported finding
their undergraduate medical education fairly or very help-
ful and only 43.5% reported that their postgraduate med-
ical education was fairly or very helpful. Further,
significantly smaller majorities of physician than labora-
tory respondents found continuing educational resources
helpful in enabling them to provide MO care; for exam-
ple, only 67.6% of physicians compared to 94.1% testing
labs and 97.1% of referring labs reported that CME was
fairly or very helpful in maintaining knowledge of MOT.
Associations between attitudes and physician 
characteristics
We explored whether physicians' responses to questions
across the 6 attitude domains reviewed above were associ-
ated with characteristics that we judged might improve a
physician's ability to make effective use of MOT services,
including whether the physician: (i) reported having ever
ordered MO testing; (ii) was a specialist rather than a fam-
ily physician; (iii) provided any  care for patients with
hematological malignancies; (iv) practiced within an aca-
demic teaching unit setting; (v) worked in a metropolitan
area (city or suburb) rather than a small town or rural
area; and (vi) was a recent graduate (graduating between
1998–2007) compared to a less recent graduate (1958 –
1997) (see Additional file 1).
Of the 36 items tested in these univariate analyses of asso-
ciation, the characteristic of having ever ordered MOT was
consistently associated (statistically significant for 24 of
36 items) with more positive attitudes and the perception
of fewer barriers. Specifically, physicians who reported
ever having ordered MOT were more likely than those
who had never ordered MOT to: (a) consider it very
important for diagnosis, prognosis and treatment now,
and in 5 years, (b) mildly or strongly agree that cancer
patients were receiving the MOT that is indicated as a
standard of care in their region or Ontario, and that
Ontario compares favourably in ensuring access in this
regard with other jurisdictions in Canada or the US; (c) be
fairly or very confident of their ability to assess whether
and which MOT was indicated; and (d) perceive their for-
mal and informal education as fairly or very helpful in
allowing them to prepare for and maintain knowledge of
MOT. Finally, physicians who reported ever having
ordered MOT were less likely than those who had never
ordered MOT to (e) perceive identified factors as barriers
that had some or a high impact on their ability to order
MOT (the sole exception was in being more likely to per-
ceive the lack of provincial coverage as a barrier).
Two other physician characteristics – being a specialist
(18/36 statistically significant associations) or providing
any care for patients with hematological malignancies
(11/36 statistically significant associations) – were typi-
cally but not uniformly associated with more positive atti-
tudes and the perception of fewer barriers, as reviewed
above. The final two physician characteristics – working in
a metropolitan area (4/36 statistically significant associa-
tions) and being a recent graduate (1/36 statistically sig-
nificant associations) – were only infrequently associated
with more positive attitudes and the perception of fewer
barriers.
Discussion
Clinical molecular oncology testing (MOT) for the
acquired genomic alterations underlying sporadic cancer
has an increasingly important role to play in the diagnosis
and treatment of cancer. Basic science research to identify
relevant biomarkers is increasing[27], but health servicesBMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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research to support the translation of discovery research
into effective clinical care is lacking[1,6]. Molecular oncol-
ogy testing is complex, and likely to be done in those few
facilities with the requisite technical and professional
expertise[28]; thus, effective delivery requires coordinated
systems of referral and reporting to ensure that relevant
testing is completed, clear reports are provided to treating
clinicians, and clinicians are empowered to use this infor-
mation in appropriate ways to guide clinical practice. In
Ontario, Canada, policy makers have begun to take an
interest in the development of effective molecular oncol-
ogy services[29], but little research is available to support
decision-making. We report the results of a postal survey
of the three key stakeholder groups involved in the effec-
tive provision of these testing services – physicians
involved in cancer care, laboratories where MOT is con-
ducted on-site (i.e., testing laboratories) and laboratories
that receive cancer samples but do not conduct MOT on-
site (i.e., referring laboratories) – to identify attitudes and
reported practices, provide a baseline data set, and suggest
areas of concern for future hypothesis-driven research.
Our results suggest that physicians, testing laboratories
and referring laboratories shared positive attitudes regard-
ing the importance of MOT for diagnosis, prognosis and
treatment now and expected it to be still more important
in 5 years. Testing labs were, however, significantly more
likely to consider MOT very important than the physicians
and referring labs that ensure appropriate referral. Further,
despite general support for the value of MOT, respondents
shared a dim view of access to needed molecular oncology
services. They were most enthusiastic about access within
their own region – approximately half of our respondents
mildly or strongly agreed that cancer patients were receiv-
Table 10: Perceived helpfulness of formal or continuing education for MOT
Physicians No. (%) Testing labs No. (%) Referring labs No. (%) p-value
Fairly helpful Very helpful Fairly helpful Very helpful Fairly helpful Very helpful Fairly or very helpful
Helpfulness of formal education in preparation for MOT
Undergraduate medical 
education
37/265 (14.0) 7/265 (2.6) 2/5 (40.0) 3/5 (60.0) 10/34 (29.4) 7/34 (20.6) < 0.001*
Postgraduate medical 
education
77/253 (30.4) 33/253 (13.0) 1/4 (25.0) 2/4 (50.0) 16/33 (48.5) 13/33 (39.4) < 0.001*
Master's degree 
(e.g., MSc, MA)
16/88 (18.2) 6/88 (6.8) 0/3 (0) 0/3 (0) 2/9 (22.2) 2/9 (22.2) 0.362*
Doctoral degree 
(e.g., PhD, DPhil)
7/65 (10.8) 12/65 (18.5) 5/15 (33.3) 6/15 (40.0) 2/7 (28.6) 3/7 (42.9) 0.001*
Post-PhD clinical training N/A N/A 2/13 (15.4) 11/13 (84.6) 4/7 (57.1) 2/7 (28.6) 0.350*
Helpfulness of continuing education resources in maintaining knowledge of MOT
Discussions with 
colleagues
120/264 (45.5) 79/264 (29.9) 5/17 (29.4) 11/17 (64.7) 18/35 (51.4) 14/35 (40.0) 0.023*
Conferences, workshops, 
meetings
122/264 (46.2) 73/264 (27.7) 6/17 (35.3) 10/17 (58.8) 17/38 (44.7) 17/38 (44.7) 0.001*
Reading journal articles 127/267 (47.6) 59/267 (22.1) 5/17 (29.4) 11/17 (64.7) 20/35 (57.1) 14/35 (40.0) < 0.001*
Continuing medical 
education (CME)
120/262 (45.8) 57/262 (21.8) 8/17 (47.1) 8/17(47.1) 15/34 (44.1) 18/34 (52.9) < 0.001
Electronic resources 
(websites, listservs, etc.)
86/258 (33.3) 35/258 (13.6) 8/17 (47.1) 7/17 (41.2) 18/35 (51.4) 8/35 (22.9) < 0.001
In-service training N/A N/A 4/10 (40.0) 2/10 (20.0) 8/22 (36.4) 5/22 (22.7) 1.000*
*Fisher exact testBMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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ing the MOT that was indicated as a standard of care in
their region. Smaller proportions agreed that the standard
of care was being met in the province as a whole, or that
Ontario compared favourably to other jurisdictions in
Canada or the US in ensuring access. Further, respondents
perceived various barriers to ordering or providing MOT.
Physicians perceived several barriers to ordering MOT,
notably a lack of clear guidelines regarding the clinical
indications for MOT, and a lack of adequate coverage by
the province's health insurance plan. Testing laboratories
that currently provided MOT on-site, and those referring
laboratories that wished to do so, emphasized the impact
of lack of funding on their ability to provide MOT, with
majorities indicating that a lack of funding for technical
staff, capital equipment (especially for referring labs), test
work up and ongoing provision of MOT services posed
some or high impact. Of note, only small minorities of
physicians and referring labs perceived a lack of clinical
demand as a barrier, but almost half of all testing labs per-
ceived it as such.
These reported results identify perceptions rather than
objective reality, and the appropriateness of reported atti-
tudes and their impact on practice is unknown. Nonethe-
less, these results do identify some issues for further
research. In particular, the limited agreement among
respondents with the suggestion that patients were receiv-
ing access to clinically indicated MOT is worrisome. In
addition, the fact that testing labs deem MOT more
important than the physicians and referring labs who
must ensure that samples are referred appropriately,
together with the relatively greater perception among test-
ing labs of reduced patient demand, may point to imped-
iments in referral that could restrict patient access.
Concern about the ability of stakeholders to ensure the
appropriate provision of MOT is enhanced by significant
differences in confidence and the perceived helpfulness of
education among respondent groups. Testing labs were
well equipped by formal and continuing education and
were confident about providing MOT. Yet referring labs,
while equally well equipped by educational resources,
were considerably less confident than testing labs in their
ability to determine whether and which MOT was indi-
cated, nor did they attract the confidence of testing labs.
Physicians reported being even less well prepared. They
were especially poorly equipped by their formal educa-
tion and expressed limited confidence in their ability to
decide whether MOT was indicated or what tests to order.
This may suggest that physicians and referring labs are less
able to make appropriate referrals for MOT than would be
advisable. Finally, despite physicians' lack of self-confi-
dence, they wished to maintain control over the selection
and interpretation of MOT. By contrast, testing labs per-
ceived a determining role for themselves in selecting
appropriate MOT and for the laboratory physician to inte-
grate MOT with other laboratory results to guide clinical
practice. These differences suggest a lack of clarity about
responsibility for the coordination and use of appropriate
MO services.
The pattern of associations between physician characteris-
tics and reported attitudes and perceived barriers is not
conclusive, but raises questions about whether the order-
ing behaviour of physicians is appropriate. Physicians
who ordered any MOT, specialists, physicians who pro-
vided any care for patients with hematological malignan-
cies, and physicians in academic teaching unit settings
were more likely than their peers (i.e., those who ordered
no MOT, family physicians, those who did not provide
hematological care, etc.) to report greater enthusiasm for
the importance of MOT, better access to needed testing,
more confidence to provide MOT and the greater helpful-
ness of formal and continuing education. Other physician
characteristics (e.g., metropolitan workplace, recent grad-
uates) were less consistently important but still significant
factors influencing more positive attitudes and experi-
ences. Some of these differences were expected, reflecting
the more established importance of MOT for the hemato-
logical malignancies and the greater responsibility of spe-
cialist than family physician providers to ensure adequate
MOT for patients in their care. Further research will be
required to determine whether these statistically signifi-
cant differences reflect appropriate patterns of practice or
suggest that ordering behaviour is driven by other factors
than clinical rationale.
Surveys reporting the attitudes and practices of laborato-
ries or physicians in genetic testing for hereditary disease
[17-19], or in molecular genetic testing more gener-
ally[20,21], have been reported, but this survey is a first to
assess the role of physicians and laboratories in ensuring
appropriate access to MOT for the sporadic cancers.
Expanded knowledge of clinically important genomic
biomarkers increases the contribution of the clinical labo-
ratory to overall patient care[30], and increases the need
for effective laboratory-clinician communication[31].
Arguably, it also increases the need for vertically inte-
grated labs that can standardize the selection of appropri-
ate testing, including MOT[28], and increases the need to
"place responsibility for primary interpretation of labora-
tory tests on laboratory professionals"[4]. This study sug-
gests that laboratories and physicians in Ontario may not
be well equipped as individual stakeholders, or as a coor-
dinated system of referral and interpretation, to provide
MOT. Deficits in education, knowledge and confidence,
and in the ability to coordinate appropriate testing,
together with perceived funding shortfalls, may compro-
mise optimal cancer care.BMC Health Services Research 2009, 9:131 http://www.biomedcentral.com/1472-6963/9/131
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The strengths of this survey include its novelty, detailed
questionnaire and rigorous follow-up to ensure a rela-
tively high response rate. Limitations result from a sam-
pling frame for physicians that relied on self-
identification by hematologists of a sub-specialty or med-
ical interest in oncology for inclusion. This is likely to
have reduced the representation of eligible hematology
respondents and may have biased the results for physi-
cians toward a more negative view of access to, or prepar-
edness for, MOT. In addition, the research reported here
fails to reflect the rapid pace of recent developments in
molecular oncology that have reinforced the value of
MOT for the hematological malignancies and demon-
strated its value for more of the solid tumours. The biasing
effect of this limitation is likely to be similar to that of a
reduced representation of hematological respondents,
producing a less positive view of the value of MOT than
might be apparent if the survey were to be run again
today. Further, data about each laboratory were provided
by one respondent, who could only partially represent the
features of organizational practice and culture that are
likely to be relevant to effective laboratory operation.
Finally, this research uses self-report, rather than objec-
tive, data on MOT use, and our results are limited by the
use of multiple tests of statistical significance on the same
data. Further research is needed to address these limita-
tions and to identify educational, training and other inter-
ventions to rectify deficits in care.
Conclusion
Physicians and laboratory professionals reported being
enthusiastic about the value of MOT for cancer care but
many did not believe that patients in their care were gain-
ing adequate access to clinically necessary testing. Further,
our results suggest that many respondents were ill
equipped as individual stakeholders, or as a coordinated
system of referral and interpretation, to provide MOT.
These challenges, together with perceived funding short-
falls, should inspire educational, training and other inter-
ventions to ensure that developments in molecular
oncology can result in optimal cancer care.
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